Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 13.07.2026 1 Actas Urol Esp (Engl Ed) 1 Adv Exp Med Biol 2 Anal Chem 1 Ann Surg Oncol 1 BMC Cancer 1 BMC Med Imaging 1 BMC Urol 1 Can J Urol 1 Cancer Cytopathol 1 Cancer Prev Res (Phila) 1 Cancer Sci 1 Cell Oncol (Dordr) 2 Cell Signal 1 Chem Commun (Camb) 1 Curr Oncol Rep 1 Curr Opin Support Palliat Care 1 Cytokine 1 Eur Urol 2 Eur Urol Oncol 1 Front Immunol 1 Future Sci OA 1 Histopathology 1 Int J Urol 1 Int Urol Nephrol 1 J Clin Oncol 1 J Immunother Cancer 1 J Korean Med Sci 1 J Magn Reson Imaging 1 J Transl Med 1 Jpn J Clin Oncol 1 Nanomedicine (Lond) 1 Nat Nanotechnol 1 Oncology 1 Public Health 1 Sci Prog 1 Support Care Cancer 3 Urol Oncol 1 Urologia 1 Urologiia 1 Virchows Arch 1 World J Urol 1 Zhonghua Wai Ke Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Actas Urol Esp (Engl Ed)

1. MONSONIS USO R, Ponce Blasco P, Canos Nebot A, Barrios Arnau L, et al
   Association Between Perioperative Blood Transfusion and Survival Outcomes After Radical Cystectomy for Bladder Cancer.
   Actas Urol Esp (Engl Ed). 2026 Jul 7:502001. doi: 10.1016/j.acuroe.2026.502001.
   PubMed         Abstract available
   
   

   
   Adv Exp Med Biol

2. MOUSA MK, Soares NC, Santos HM
   LC-MS-Based Metabolomics and Proteomics Sample Preparation of Urine: Methods and Multi-Omics Integration.
   Adv Exp Med Biol. 2026;1510:1-20.
   PubMed         Abstract available
   
   

   
   Anal Chem

3. WANG ZQ, Song Q, Liu JY, Peng CY, et al
   A Solid-State Near-Infrared Fluorescent Probe by a Synergistic Extended Conjugated System for Detecting Cys with Long-Term Imaging in Orthotopic Bladder Cancer.
   Anal Chem. 2026 Jul 4. doi: 10.1021/acs.analchem.6c03199.
   PubMed         Abstract available
   
   
4. YU L, Liu T, Cai Y, Gai Y, et al
   An Interface-Regulated Electrochemical Biosensing Platform Based on the Cascade Amplification of Primer Exchange Reaction and CRISPR/Cas12a for Noninvasive Bladder Cancer Diagnosis.
   Anal Chem. 2026 Jul 7. doi: 10.1021/acs.analchem.6c02591.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. GABRIEL PE, Seisen T, Xylinas E, Duquesne H, et al
   Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee.
   Ann Surg Oncol. 2026;33:7790-7800.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. WANG Y, Ailiyaer A, Chen S, Wang W, et al
   Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
   BMC Cancer. 2026;26:813.
   PubMed         Abstract available
   
   

   
   BMC Med Imaging

7. LIU W, Gong B, Zhang G, Guo Y, et al
   Development of multiphasic CT-based delta-radiomics model for predicting postoperative recurrence risk in bladder cancer.
   BMC Med Imaging. 2026 Jul 7. doi: 10.1186/s12880-026-02554.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. FAKHOURI F, Candido P, Pimenta R, Guimaraes VR, et al
   The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells.
   BMC Urol. 2026 Jul 4. doi: 10.1186/s12894-026-02241.
   PubMed         Abstract available
   
   

   
   Can J Urol

9. LI A, Tang C, Wei X, Liu F, et al
   Endourological autologous bypass-ureteroplasty for anastomotic atresia in orthotopic neobladder: a novel surgical approach and case report.
   Can J Urol. 2026;33:643-648.
   PubMed         Abstract available
   
   

   
   Cancer Cytopathol

10. BARTH G, Koch S, Ecke TH
    Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.
    Cancer Cytopathol. 2026;134:e70130.
    PubMed         Abstract available
    
    

    
    Cancer Prev Res (Phila)

11. MARRONE MT, Bagley E, Butler KR, Couper DJ, et al
    Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.
    Cancer Prev Res (Phila). 2026 Jul 6. doi: 10.1158/1940-6207.CAPR-25-0499.
    PubMed         Abstract available
    
    

    
    Cancer Sci

12. WANG T, Liao X, Zhang J, Xu X, et al
    Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.
    Cancer Sci. 2026 Jul 6. doi: 10.1111/cas.70455.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

13. XU H, Yang C, Fu Q, Zeng S, et al
    Hypoxia-induced exosomal LNCOC1 orchestrates bladder cancer progression via the YBX1/PIK3CA axis and serves as a potential liquid biopsy biomarker.
    Cell Oncol (Dordr). 2026 Jul 7. doi: 10.1007/s13402-026-01257.
    PubMed         Abstract available
    
    

    
    Cell Signal

14. CHEN Y, Zhuang J, Yu H, Li K, et al
    Hypoxia remodels circSTX6 nuclear export through URH49-ALYREF to drive IGF1-mediated bladder cancer progression.
    Cell Signal. 2026;147:112723.
    PubMed         Abstract available
    
    
15. XIANG L, Li Y, Dong X, Yan Y, et al
    EIF4A3 facilitates METTL3-mediated m(6)A methylation of circPCMTD1 to drive bladder cancer progression via miR-3681-5p/HPSE axis.
    Cell Signal. 2026 Jul 7:112725. doi: 10.1016/j.cellsig.2026.112725.
    PubMed         Abstract available
    
    

    
    Chem Commun (Camb)

16. GUAN J, Jiang X, Lv Y, Xue Y, et al
    Visualizing NO(2)(-)/NAD(P)H metabolic crosstalk in E. coli-infected bladder cancer via a dual-responsive probe.
    Chem Commun (Camb). 2026 Jul 9. doi: 10.1039/d6cc02834.
    PubMed         Abstract available
    
    

    
    Curr Oncol Rep

17. PETRELLI F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al
    Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.
    Curr Oncol Rep. 2026;28:72.
    PubMed         Abstract available
    
    

    
    Curr Opin Support Palliat Care

18. PETERSEN E, Sheldon J, Torgerson H, Kirschenbaum M, et al
    The impact of cachexia and sarcopenia in bladder cancer.
    Curr Opin Support Palliat Care. 2026 Jul 9. doi: 10.1097/SPC.0000000000000811.
    PubMed         Abstract available
    
    

    
    Cytokine

19. STROJNY Z, Kanikowska D, Kanikowska A, Tomczak Z, et al
    The significance of vascular endothelial growth factor and systemic inflammatory reaction in bladder cancer patients.
    Cytokine. 2026;205:157190.
    PubMed         Abstract available
    
    

    
    Eur Urol

20. MIAO J, Yi X
    Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org
    Eur Urol. 2026 Jul 9:S0302-2838(26)02241-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

21. THIBAULT C, Blons H, Allory Y, Harba A, et al
    Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
    Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00182-3. doi: 10.1016/j.euo.2026.
    PubMed         Abstract available
    
    
22. GREIDANUS J, van Dijk-de Haan MC, Messina A, Calareso G, et al
    MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.
    Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00154-9. doi: 10.1016/j.euo.2026.
    PubMed         Abstract available
    
    

    
    Front Immunol

23. ZHANG X, Ge P, Chen Q, Wang S, et al
    Liquid-liquid phase separation-associated gene networks link EMT and ferroptosis to define a PDGFRB-centered prognostic signature in bladder cancer.
    Front Immunol. 2026;17:1846096.
    PubMed         Abstract available
    
    

    
    Future Sci OA

24. YANG L, Zhang JM, Chen YJ, Wei ZQ, et al
    Multi-omics profiling identifies CDK1 as a key mediator of mitosis through the PTN pathway in bladder cancer.
    Future Sci OA. 2026;12:2696931.
    PubMed         Abstract available
    
    

    
    Histopathology

25. YAPRAK BAYRAK B, Kosemehmetoglu K, Ozbek B, Simsek S, et al
    Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E-cadherin, P120, HER2 and TRPS1.
    Histopathology. 2026;89:338-346.
    PubMed         Abstract available
    
    

    
    Int J Urol

26. KIKUCHI E, Kobayashi T, Shono M, Hoffman J, et al
    Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.
    Int J Urol. 2026;33:e70558.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

27. GAO M, Liu F, Wen J, Shen Y, et al
    Beyond VI-RADS: incremental value of quantitative mpMRI measurements for identifying muscle-invasive bladder cancer.
    Int Urol Nephrol. 2026 Jul 10. doi: 10.1007/s11255-026-05267.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. THIBAULT C, Bennamoun M, Flechon A, Gravis G, et al
    Neoadjuvant Durvalumab +/- Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
    J Clin Oncol. 2026;44:1921-1932.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

29. SU YL, Huang SY, Kuo CW, Xiao LY, et al
    Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
    J Immunother Cancer. 2026;14:e014770.
    PubMed         Abstract available
    
    

    
    J Korean Med Sci

30. SIM KC, Sung DJ, Han NY, Han YE, et al
    Correlation Between the Natural Course and Magnetic Resonance Imaging Features of Bacillus Calmette-Guerin-Related Granulomatous Prostatitis in Patients With Bladder Cancer.
    J Korean Med Sci. 2026;41:e178.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

31. MUGLIA VF, Reis RB
    Editorial for "A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels".
    J Magn Reson Imaging. 2026 Jul 6. doi: 10.1002/jmri.70416.
    PubMed        
    
    

    
    J Transl Med

32. OTO J, Herreros-Pomares A, Verger P, Herranz R, et al
    A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.
    J Transl Med. 2026 Jul 6. doi: 10.1186/s12967-026-08570.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

33. YONESE I, Koga F, Toide M, Maezawa Y, et al
    Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).
    Jpn J Clin Oncol. 2026;56:885-893.
    PubMed         Abstract available
    
    

    
    Nanomedicine (Lond)

34. PAN CX, Mossanen M, Ellis JL, Ma AH, et al
    Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.
    Nanomedicine (Lond). 2026 Jul 8:1-7. doi: 10.1080/17435889.2026.2693194.
    PubMed         Abstract available
    
    

    
    Nat Nanotechnol

35. YIM W, Kang H, Kang BH, McGinnis ME, et al
    Publisher Correction: Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
    Nat Nanotechnol. 2026 Jul 6. doi: 10.1038/s41565-026-02239.
    PubMed        
    
    

    
    Oncology

36. DI LORENZO G
    Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Oncology. 2026 Jul 9:1-7. doi: 10.1159/000553466.
    PubMed        
    
    

    
    Public Health

37. DOHERTY R, Kiadaliri A, Hajizadeh M
    Socioeconomic inequalities in bladder cancer mortality in Canada: Temporal trends over three decades, 1990-2019.
    Public Health. 2026;258:106396.
    PubMed         Abstract available
    
    

    
    Sci Prog

38. CHEN N, Cai J, Feng J, He Y, et al
    A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045.
    Sci Prog. 2026;109:368504261466968.
    PubMed         Abstract available
    
    

    
    Support Care Cancer

39. LI Z, Fu Y, Zhang J, Wang Y, et al
    Challenges in postoperative self-management for patients with bladder cancer and urinary stoma: a qualitative study.
    Support Care Cancer. 2026;34:740.
    PubMed         Abstract available
    
    

    
    Urol Oncol

40. YAJIMA S, Imasato N, Hashimoto T, Kobayashi S, et al
    Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.
    Urol Oncol. 2026;44:13-24.
    PubMed         Abstract available
    
    
41. SINGH V, Aggarwal A, Akhtar MR, Pandey M, et al
    Comparison of quality of life and sexual function after ileal vs. sigmoid orthotopic neobladder reconstruction following nerves, vas deferens, and seminal vesicle-sparing radical cystectomy: A prospective randomized study.
    Urol Oncol. 2026;44:82-91.
    PubMed         Abstract available
    
    
42. MOYER JA, Ashraf M, Mi L, Zganjar AJ, et al
    Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 9:S1078-1439(26)00568-5. doi: 10.1016/j.urolonc.2026.
    PubMed         Abstract available
    
    

    
    Urologia

43. SHIRANI F, Lashay A
    Cutaneous ureterostomy versus ileal conduit as urinary diversion in patients with muscle-invasive bladder cancer undergoing radical cystectomy: A comparative analysis of high-risk cases.
    Urologia. 2026 Jul 4:3915603261461658. doi: 10.1177/03915603261461658.
    PubMed         Abstract available
    
    

    
    Urologiia

44. ZHESTKOV I A, Kamalov D M, Oleynikova N A, Nesterova O Y, et al
    [Tumor-associated fibroblasts and clinical and morphological features of bladder cancer].
    Urologiia. 2025;:90-94.
    PubMed         Abstract available
    
    

    
    Virchows Arch

45. SCHERPING AK, Tomasik B, Luzha J, Schostak M, et al
    Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.
    Virchows Arch. 2026 Jul 6. doi: 10.1007/s00428-026-04639.
    PubMed         Abstract available
    
    

    
    World J Urol

46. ZOU XC, Yu ZJ, Yuan YY, Chao HC, et al
    Interpretable machine learning model of contrast-enhanced CT radiomics for predicting post-BCG recurrence in high-grade non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:486.
    PubMed         Abstract available
    
    

    
    Zhonghua Wai Ke Za Zhi

47. CAI LK, Yang X, Cao Q, Tian W, et al
    [MRI-based deep learning model for preoperative prediction of urothelial carcinoma with variant histology of bladder: a retrospective, multicenter study].
    Zhonghua Wai Ke Za Zhi. 2026;64:752-759.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum